Bull Call Spreads
[Debit]
Bull Put Spreads
[Credit]
Bear Call Spreads
[Credit]
Bear Put Spreads
[Debit]
Call Butterflies
[Short ATM, Long OTM]
Call Butterflies
[Long ATM, Short OTM]
Put Butterflies
[Short ATM, Long OTM]
Put Butterflies
[Long ATM, Short OTM]
Iron Butterflies
[Short ATM, Long OTM]
Iron Butterflies
[Long ATM, Short OTM]
Iron Condors
[Long Inner, Short Outer]
Iron Condors
[Short Inner, Long Outer]
Straddles
[At-The-Money]
Get Cash Back and $0 Commissions
+ The Power of TradeStation
Yolowire 13-Mar-2024 4:07 PM
A California-based %Biotech company saw its shares soar on Wednesday, a day following the companys Q4 earnings announcement. With analysts expecting a net loss of $0.16 per diluted share, %HeronTherapeutics (NASDAQ:HRTX) Q4 results came in at a net loss of $0.07 per diluted share.
Traders naturally were optimistic on the better-than-expected results as shares traded up to $3.22/share (+36.44%) at the early session high. This move occurred in tandem with the biotech sector as a whole finding success as of late.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.
COMTEX_449205306/2797/2024-03-13T15:40:57